Sanofi has entered into a definitive merger agreement to acquire Vigil Neuroscience for $8.00 per share in cash upfront, with an additional $2.00 per share contingent value right tied to VG-3927's first commercial sale.
Phase 2 study results reveal that Sanofi's investigational riliprubart reduced plasma neurofilament light levels by 31% in patients with chronic inflammatory demyelinating polyneuropathy.
Annexon anticipates a Biologics License Application (BLA) submission for ANX005 in the first half of 2025, potentially transforming Guillain-Barré Syndrome (GBS) treatment.
Sanofi's riliprubart demonstrated significant disease-controlling benefits across all patient cohorts in a Phase 2 study for chronic inflammatory demyelinating polyneuropathy (CIDP), including those who failed standard treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.